Watson Said to Be in Talks to Buy Swiss Drugmaker Actavis

Watson Pharmaceuticals Inc. is in talks to buy Actavis Group hf, a Swiss maker of generic drugs, for as much as 5.5 billion euros ($7.3 billion), a person with knowledge of the matter said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.